10x Genomics (NASDAQ:TXG) Shares Down 6.7% – Here’s What Happened

13 Dec 2025, 11:16 by Jessica Moore · The Cerbat Gem

10x Genomics (NASDAQ:TXG – Get Free Report) fell 6.7% during mid-day trading on Thursday . The stock traded as low as $16.40 and last traded at $16.3510. 462,460 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 3,185,433 shares. The stock had previously closed at $17.53.

Wall Street Analysts Forecast Growth

TXG has been the topic of several research reports. Wall Street Zen lowered 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 price target (up previously from $17.00) on shares of 10x Genomics in a research report on Monday, December 1st. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. UBS Group raised their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Barclays lifted their target price on shares of 10x Genomics from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.35.

View Our Latest Analysis on TXG

10x Genomics Price Performance

The company has a 50 day moving average price of $15.07 and a 200 day moving average price of $13.26. The firm has a market cap of $1.96 billion, a PE ratio of -24.94 and a beta of 2.15.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. The company had revenue of $149.00 million for the quarter, compared to analysts’ expectations of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. 10x Genomics’s revenue was down 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. On average, equities analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $251,959.00. Following the completion of the sale, the chief executive officer owned 1,021,556 shares in the company, valued at $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the transaction, the insider directly owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 33,432 shares of company stock valued at $635,208 over the last ninety days. Corporate insiders own 9.39% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

Institutional investors have recently made changes to their positions in the stock. Allworth Financial LP increased its holdings in shares of 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. True Wealth Design LLC increased its holdings in 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after buying an additional 3,369 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock valued at $45,000 after acquiring an additional 3,119 shares during the period. US Bancorp DE boosted its stake in shares of 10x Genomics by 314.5% during the 1st quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after acquiring an additional 4,532 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $56,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Company Profile

(Get Free Report)